重症肌无力不同抗体类型的免疫学特征

摘要
图/表
参考文献(20)
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的分析不同抗体分型重症肌无力（MG）患者的临床特点及与其他免疫指标异常的关系。方法选取2017年1月～2018年12月深圳市人民医院和深圳市龙华区中心医院收治的155例MG 患者进行研究，使用酶联免疫吸附法测定患者血清中的抗乙酰胆碱受体抗体（AChR Ab）、肌肉特异性激酶抗体（MuSK Ab）。根据AChR Ab、MuSK Ab 的表达情况对患者进行分组，分为AChR Ab 阳性（+）MG 组（103例），MuSK Ab 阳性（+）MG 组（13例）以及双抗体阴性（DSN）MG 组（39例），分析三组的临床表现、实验室检查、胸腺病理类型和治疗方案。结果本研究纳入的MG 患者中，AChR Ab（+）MG、MuSK Ab（+）MG、DSN MG 构成比分别为：66.4%、8.4%、25.2%。MuSK Ab（+）MG 组相较于其余两组更易累及球部肌肉，差异有统计学意义（P＜0.05）。三组患者出现肌无力危象的比例比较，差异无统计学意义（P＞0.05）。AChR Ab（+）MG 组相比于其余两组甲状腺异常率、自身抗体阳性率更高，差异有统计学意义（P＜0.05）。AChR Ab（+）MG 组、MuSK Ab（+）MG 组、DSN MG 组三组间的胸腺瘤罹患率分别为55.3%、23.1%及25.6%，组间分析，AChR Ab（+）MG 组胸腺瘤罹患率相比于其余两组更高，差异有统计学意义（P＜0.05）。结论 AChR Ab、MuSK Ab 不同表达情况下，MuSK Ab（+）MG 起病症状以球部肌肉-眼部肌肉受累较多，但累及肌群较局限。AChR Ab（+）MG 易出现甲状腺功能异常和自身抗体异常，且AChR Ab（+）MG 更易罹患胸腺瘤。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：重症肌无力, 抗乙酰胆碱受体抗体, 肌肉特异性激酶抗体, 甲状腺功能, 自身抗体

Abstract：Objective To explore the clinical characteristics of different antibody types and the relationship with other immune factors in myasthenia gravis.Methods A total of 155 patients with myasthenia gravis （MG） who were admitted to Shenzhen People′s Hospital and Shenzhen Longhua District Central Hospital from January 2017 to December 2018 were enrolled in the study.The anti-acetylcholine receptor antibody (AChR Ab) and antibody to muscle-specific kinase(MuSK Ab) in serum were determined by enzyme-linked immunosorbent assay.Patients were divided into AChR Ab positive (+) MG group,MuSK Ab positive (+) MG group and double seronegative (DSN) MG group according to the expression of AChR Ab antibody and MuSK Ab.The clinical manifestations,laboratory tests,thymic pathology and treatment programs of the three groups were analyzed.Results Among the 155 MG patients included in this study,the composition ratios of AChR Ab (+)MG,MuSK Ab (+)MG,and DSN MG were 66.4%,8.4%,and 25.2% respectively.After comparison,MuSK Ab (+) MG group was more likely to involve the muscles of the ball than the remaining two groups,the difference was statistically significant (P＜0.05).There was no significant difference in the proportion of myasthenic crisis among the all groups (P＞0.05).The AChR Ab(+)MG group had a higher thyroid abnormality rate and autoantibody positive rate than the remaining two groups,and the difference was statistically significant (P＜0.05).The incidence of thymoma among the AChR Ab(+)MG group,MuSK Ab(+)MG group,and DSN MG group was 55.3%,23.1%,and 25.6%,respectively.Comparing each subgroup,the AChR Ab(+)MG group had a higher the incidence of thymoma than the remaining two groups,the difference was statistically significant (P＜0.05).Conclusion With the different expressions of AChR Ab and MuSK Ab,MuSK Ab(+)MG was more likely to present bulbar muscles or extraocular muscles and the muscles are more limited.AChR Ab (+)MG is prone to abnormal thyroid function and has a higer autoantibody positive rate.AChR Ab(+)MG are prone to be associated with thymoma.

Key words： Myasthenia gravis Anti-acetylcholine receptor antibody Antibody to muscle-specific kinase Thyroid dysfunction Autoantibody

通讯作者: 黄莹，女，硕士

作者简介: 罗翰(1989-)，男，硕士，主治医师，研究方向：神经内科

引用本文:

罗翰；徐铅辉王倩；赵增霞；刘春柏；黄莹. 重症肌无力不同抗体类型的免疫学特征[J]. 中国当代医药, 2020, 27(34): 21-25.
LUO Han； XU Qian-hui； WANG Qian； ZHAO Zeng-xia； LIU Chun-bai；HUANG Ying. Immunologic characteristics of different antibody types in myasthenia gravis. 中国当代医药, 2020, 27(34): 21-25.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2020/V27/I34/21

[3]	Di Stefano V，Lupica A，Rispoli MG，et al.Rituximab in AChR subtype of myasthenia gravis：systematic review[J].J Neurol Neurosurg Psychiatry，2020，91（4）：392-395.
[4]	Diaz-Manera J，Martinez-Hernandez E，Querol L，et al.Longlasting treatment effect of rituximab in MuSK myasthenia[J].Neurology，2012，78（3）：189-193.
[5]	Fan L，Ma S，Yang Y，et al.Clinical differences of early and late-onset myasthenia gravis in 985 patients[J].Neurol Res，2019，41（1）：45-51.
[7]	Evoli A，Alboini PE，Damato V，et al.Myasthenia gravis with antibodies to MuSK：an update[J].Ann N Y Acad Sci，2018，1412（1）：82-89.
[9]	Nacu A，Andersen JB，Lisnic V，et al.Complicating autoimmune diseases in myasthenia gravis：a review[J].Autoimmunity，2015，48（6）：362-368.
[10]	Chen P，Li Y，Huang H，et al.Imbalance of the two main circulating dendritic cell subsets in patients with myasthenia gravis[J].Clin Immunol，2019，205（6）：130-137.
[11]	Alekseeva TM，Kreis OA，Gavrilov YV，et al.Impact of autoimmune comorbidity on fatigue，sleepiness and mood in myasthenia gravis[J].J Neurol，2019，266（8）：2027-2034.
[13]	Renton AE，Pliner HA，Provenzano C，et al.A genome-wide association study of myasthenia gravis[J].JAMA Neurol，2015，72（4）：396-404.
[14]	Mevorach D，Perrot S，Buchanan NM，et al.Appearance of systemic lupus erythematosus after thymectomy：four case reports and review of the literature[J].Lupus，1995，4（1）：33-37.
[17]	Giraud M，Beaurain G，Yamamoto AM，et al.Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies[J].Neurology，2001，57（9）：1555-1560.
[18]	Yi JS，Guptill JT，Stathopoulos P，et al.B cells in the pathophysiology of myasthenia gravis[J].Muscle Nerve，2018，57（2）：172-184.
[19]	Barnett C，Katzberg H，Nabavi M，et al.The quantitative myasthenia gravis score：comparison with clinical，electrophysiological，and laboratory markers[J].JClin Neuromuscul Dis，2012，13（4）：201-205.
[20]	Jing F，Cui F，Chen Z，et al.Clinical and Electrophysiological Markers in Myasthenia Gravis Patients[J].Eur Neurol，2015，74（1-2）：22-27.
[6]	朱慧，高枫，袁云，等.不同重症肌无力患者人群血清抗体检测的临床意义[J].中国神经免疫学和神经病学杂志，2018，2（25）：87-90.
[8]	马艳艳.重症肌无力患者基于抗体分型的临床亚组分析[D].西安：西安医学院，2019.
[12]	Aguirre F，Villa AM.Myasthenia gravis.Register of 190 cases in a single center[J].Medicina（B Aires），2020，80（1）：10-16.
[15]	京津冀重症肌无力联盟.重症肌无力外科治疗京津冀专家共识[J].天津医药，2020，4（48）：327-332.
[1]	Xin H，Harris LA，Aban IB，et al.Examining the Impact of Refractory Myasthenia Gravis on Healthcare Resource Utilization in the United States：Analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample[J].J Clin Neurol，2019，15（3）：376-385.
[2]	Cebi M，Durmus H，Yilmaz V，et al.Relation of HLA-DRB1 to IgG4 autoantibody and cytokine production in musclespecific tyrosine kinase myasthenia gravis （MuSK-MG）[J].Clin Exp Immunol，2019，197（2）：214-221.
[16]	李劲频，徐宏炎，莫雪安.胸腺切除治疗非胸腺瘤重症肌无力的研究进展[J].中国医药导报，2019，16（16）：54-56.